<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02250976</url>
  </required_header>
  <id_info>
    <org_study_id>HL-PIF-103</org_study_id>
    <nct_id>NCT02250976</nct_id>
  </id_info>
  <brief_title>The Pharmacokinetic Study of the Fixed-dose Combination of Micronized Fenofibrate and Pitavastatin Ca</brief_title>
  <official_title>A Clinical Trial to Evaluate the Pharmacokinetics of the Fixed-dose Combination of Micronized Fenofibrate and Pitavastatin Ca Under Fed Condition in Healthy Male Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hanlim Pharm. Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hanlim Pharm. Co., Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To develop combination product of micronized fenofibrate plus pitavastatin, we would like to
      evaluate the comparative pharmacokinetics and safety of fixed-dose combination(micronized
      fenofibrate160mg+pitavastatin Ca 2mg) versus coadministration of Lipilfen
      cap.160mg(micronized fenofibrate160mg) and Livaro tab. 2mg(pitavastatin Ca 2mg) under fed
      condition in healthy male volunteers.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>September 2014</start_date>
  <completion_date type="Anticipated">November 2014</completion_date>
  <primary_completion_date type="Anticipated">November 2014</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>AUClast(area under the curve) of fenofibric acid</measure>
    <time_frame>Pre-dose(0h), 1, 2, 3, 4, 5, 5.5, 6, 6.5, 8, 12, 24, 48, 72, 96h(15 points)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmax(maximum concentration) of fenofibric acid</measure>
    <time_frame>Pre-dose(0h), 1, 2, 3, 4, 5, 5.5, 6, 6.5, 8, 12, 24, 48, 72, 96h(15 points)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>AUClast(area under the curve) of pitavastatin</measure>
    <time_frame>Pitavastatin : Pre-dose(0h), 0.25, 0.5, 0.75, 1, 1.25, 1.5, 2, 3, 4, 5, 5.5, 6, 6.5, 8, 12, 24, 48, 72h(18 points)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmax(maximum concentration) of pitavastatin</measure>
    <time_frame>Pitavastatin : Pre-dose(0h), 0.25, 0.5, 0.75, 1, 1.25, 1.5, 2, 3, 4, 5, 5.5, 6, 6.5, 8, 12, 24, 48, 72h(18 points)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>AUCinf(area under the curve) of fenofibric acid</measure>
    <time_frame>Pre-dose(0h), 1, 2, 3, 4, 5, 5.5, 6, 6.5, 8, 12, 24, 48, 72, 96h(15 points)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tmax(time to Maximum Plasma Concentration) of fenofibric acid</measure>
    <time_frame>Pre-dose(0h), 1, 2, 3, 4, 5, 5.5, 6, 6.5, 8, 12, 24, 48, 72, 96h(15 points)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>t1/2(half life) of fenofibric acid</measure>
    <time_frame>Pre-dose(0h), 1, 2, 3, 4, 5, 5.5, 6, 6.5, 8, 12, 24, 48, 72, 96h(15 points)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUCinf(area under the curve) of pitavastatin</measure>
    <time_frame>Pre-dose(0h), 0.25, 0.5, 0.75, 1, 1.25, 1.5, 2, 3, 4, 5, 5.5, 6, 6.5, 8, 12, 24, 48, 72h(18 points)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tmax(time to Maximum Plasma Concentration) of pitavastatin</measure>
    <time_frame>Pre-dose(0h), 0.25, 0.5, 0.75, 1, 1.25, 1.5, 2, 3, 4, 5, 5.5, 6, 6.5, 8, 12, 24, 48, 72h(18 points)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>t1/2(half life) of pitavastatin</measure>
    <time_frame>Pre-dose(0h), 0.25, 0.5, 0.75, 1, 1.25, 1.5, 2, 3, 4, 5, 5.5, 6, 6.5, 8, 12, 24, 48, 72h(18 points)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with adverse events</measure>
    <time_frame>Participants will be followed for the duration of hospital stay, and expected period for maximum 7 days from the discharge</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Healthy Male Volunteers</condition>
  <arm_group>
    <arm_group_label>Livasupril Cap.160/2mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Fenofibrate pellet ( as micronized fenofibrate 160mg) and Pitavastatin Ca 2mg
once a day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Lipilfen cap.160mg, Livaro tab. 2mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Lipilfen cap.160mg : Micronized fenofibrate 160mg , Livaro tab. 2mg : Pitavastatin ca 2mg
Coadministariton of Lipilfen cap.160mg and Livaro tab. 2mg, once a day</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Livasupril Cap.160/2mg</intervention_name>
    <description>Fenofibrate pellet( as micronized fenofibrate 160mg) and Pitavastatin Ca 2mg</description>
    <arm_group_label>Livasupril Cap.160/2mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lipilfen cap. 160mg</intervention_name>
    <description>Micronized fenofibrate 160mg</description>
    <arm_group_label>Lipilfen cap.160mg, Livaro tab. 2mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Livaro tab. 2mg</intervention_name>
    <description>Pitavastatin Ca 2mg</description>
    <arm_group_label>Lipilfen cap.160mg, Livaro tab. 2mg</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy male subjects age 19 to 55 at the screening visit

          -  Body weight≥50kg and within Ideal body weight±20%

          -  Subject who is judged to be eligible according to clinical laboratory tests including
             hematological examination, blood chemistry examination, urine analysis

          -  Subject who volunteerly determined to participate in and agreed to comply with
             precautions after totally understand the detailed explanations about this study

        Exclusion Criteria:

          -  Subject with serious active cardiovascular, respiratory, hepatology, renal,
             hematologic, gastrointestinal, immunologic, dermal, neurologic, or psychological
             disease or history of such disease

          -  Subject with symptoms of acute disease within 28days prior to study medication dosing

          -  Subject with known for history which affect on the absorption, distribution,
             metabolism or excretion of drug

          -  Subject with clinically significant active chronic disease

          -  Subject with any of the following conditions in laboratory test i. AST(aspartate
             aminotransferase) or ALT(alanine transferase) &gt; upper normal limit × 1.5 ii. Total
             bilirubin &gt; upper normal limit × 1.5 iii. renal failure with Creatinine clearance &lt;
             50mL/min iv. creatine phosphokinase &gt; upper normal limit × 2

          -  Positive test results for hepatitis B virus surface antigen, anti-hepatitis C virus
             antibody, human immunodeficiency virus antigen/antibody,venereal disease research
             laboratory test

          -  Use of any prescription medication within 14 days prior to study medication dosing

          -  Use of any medication such as over-the-counter medication including oriental
             medication within 7 days prior to study medication dosing

          -  Subject with clinically significant allergic disease (except for mild allergic
             rhinitis and mild allergic dermatitis that are not needed to administer drug)

          -  Subject with known for hypersensitivity reaction to fenofibrate, fenofibric acid or
             statin

          -  gallbladder disease

          -  Subject who experiences photo-allergy or photo-toxicity during administrating fibrates
             or ketoprofen

          -  Subject with genetic deficiency such as galactose intolerance, Lapp lactose deficiency
             or glucose-galactose malabsorption

          -  Subject who is not able to taking the institutional standard meal

          -  Subject with whole blood donation within 60days, component blood donation within
             20days

          -  Subjects receiving blood transfusion within 30days prior to study medication dosing

          -  Participation in any clinical investigation within 60days prior to study medication
             dosing

          -  Continued excessive use of caffeine (caffeine &gt; five cups/day),
             alcohol(alcohol&gt;30g/day) and severe heavy smoker(cigarette &gt; 10 cigarettes per day)

          -  Subjects with decision of nonparticipation through investigator's review due to
             laboratory test results or other excuse such as non-responding to request or
             instruction by investigator
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Young-Ran Yoon, M.D., Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Kyungpook National University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Young-Ran Yoon, M.D., Ph.D.</last_name>
    <phone>82 53 420 4950</phone>
    <email>yry@knu.ac.kr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Hyun-Woo Jun, R.N.</last_name>
    <phone>82 53 200 6942</phone>
    <email>jjhww@naver.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Kyungpook National University Hospital</name>
      <address>
        <city>Daegu</city>
        <zip>700-721</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Young-Ran Yoon, M.D.,Ph.D.</last_name>
      <phone>82 53 420 4950</phone>
      <email>yry@knu.ac.kr</email>
    </contact>
    <contact_backup>
      <last_name>Hyun-Woo Jun, R.N.</last_name>
      <phone>82 53 200 6942</phone>
      <email>jjhww@naver.com</email>
    </contact_backup>
    <investigator>
      <last_name>Young-Ran Yoon, M.D.,Ph.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>September 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 23, 2014</study_first_submitted>
  <study_first_submitted_qc>September 24, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 26, 2014</study_first_posted>
  <last_update_submitted>September 24, 2014</last_update_submitted>
  <last_update_submitted_qc>September 24, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 26, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fenofibrate</mesh_term>
    <mesh_term>Pitavastatin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

